Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026

Published by KuicK Research Product code 922698
Published Content info 384 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026
Published: January 17, 2020 Content info: 384 Pages
Description

"Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

  • Global Transdermal Patch Market Opportunity: > US$ 15 Billion
  • Global Transdermal Patch Clinical Pipeline: 100 Patches In Trials
  • Clinical Insight on 66 Commercially/Marketed Transdermal Patches
  • Global Transdermal Patch Clinical Trials Insight by Company, Drug Class, Indication & Patent Information
  • Regional Trends & Market Insight: US, Europe & Asia-Pacific
  • Dosage & Price Insight on Transdermal Patch
  • Global Transdermal Patch Market Future Prospects

The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" research report unravels the in-depth analysis and present statistical and non-statistical information related to the current market trends that are prevalent at the global and regional level. In addition to this, the report successfully delivers the information about the sales , dosage and price of the medications that are delivered through this route. Report also discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market and highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.

Since the advent of the transdermal drug delivery technique, there has been a continuous rise in the market of transdermal patches globally. The market growth is attributed to the advantages that are associated with the patch technique such as painless and non-invasive administration of the medication, ease of administration and the prolonged activation of the drug inside the body. The availability of large number of transdermal delivery system in the market is continuously proving to be a breakthrough and is currently undergoing by huge commercial success.

Transdermal patches offer many benefits over traditional drug delivery methodologies like pill, powder, or liquid medication. The most important and the fundamental benefit of using patches is the direct-to-bloodstream delivery while bypassing the liver's metabolic activity. This method of drug delivery is therefore a boon to the patients suffering from hepatic disorders as stress to the liver is simply bypassed. A patient's body heat activates a patch, prompting it to begin releasing medication through the skin and into the bloodstream. Thus, the innovators have enough good need for development of medications mediating through this drug delivery system.

Transdermal patches can be designed to provide prolonged and controlled release of certain drugs, which can be convenient for pain-relief drugs, nicotine, and hormone products. For instance, granisetron transdermal system is a transdermal patch used to treat chemotherapy-induced nausea and vomiting in a regulated way. The alternative forms-intravenous injections and oral tablets, both pose challenges for patients, whereas transdermal delivery provides a more comfortable and patient-friendly delivery method.

It can be well witnessed that the patch technology is playing its part and the medication in this segment have improved a lot. Clinicians wherever possible and required are more of inclined towards its use; reasons maybe several either the condition of the patient or the extra-long duration of the therapy. The need of transdermal patch drug delivery has already gained momentum and is sure to play its part in the global pharmaceutical market.

Table of Contents

Table of Contents

1. Prologue to Transdermal Patch

  • 1.1. Overview of Transdermal Patch
  • 1.2. Relevance of Transdermal Patch

2. Types of Transdermal Patches

  • 2.1. Single/ Multiple-Layer Drug-in-Adhesive
  • 2.2. Reservoir Transdermal Patches
  • 2.3. Matrix Based Transdermal Patches
  • 2.4. Vapor Patch
  • 2.5. Active and Passive Patch

3. Mechanism of Transdermal Patch Drug Delivery

  • 3.1. Properties of Transdermal Therapeutics
  • 3.2. Components of Transdermal Patch
  • 3.3. Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch
  • 3.4. Transdermal Patch v/s Traditional Drug Delivery Methods

4. Global Transdermal Patch Market Insight

  • 4.1. Global Market Scenario
  • 4.2. Regional Market Trends
    • 4.2.1. United States
    • 4.2.2. Europe
    • 4.2.3. Asia Pacific

5. Transdermal Patches for Cardiovascular Diseases-Availability, Dosage & Price Analysis

  • 5.1. Clonidine Transdermal Patch (Catapres-TTS)
  • 5.2. Nitro Glycerin Transdermal Patch

6. Opioid Drug Containing Transdermal Patches-Availability, Dosage & Price Analysis

  • 6.1. Fentanyl Transdermal Patch (Duragesic)
  • 6.2. Buprenorphine Transdermal Patch (Butrans Patch)

7. Transdermal Patches for Neurological Disorders-Availability, Dosage & Price Analysis

  • 7.1. Selegiline Transdermal Patch (Emsam)
  • 7.2. Scopolamine Transdermal Patch (Transderm-Scop)
  • 7.3. Rivastigmine Transdermal Patch (Exelon)
  • 7.4. Methylphenidate Transdermal Patch (Daytrana)

8. Transdermal Patch in Hormonal Therapy-Availability, Dosage & Price Analysis

  • 8.1. Estradiol Transdermal Patch
    • 8.1.1. Alora
    • 8.1.2. Vivelle-Dot
  • 8.2. Testosterone Transdermal Patch (Androderm)
  • 8.3. Ethinyl Estradiol & Norelgestromin Transdermal Patch (Xulane)

9. Transdermal Patches for Other Conditions-Availability, Dosage & Price Analysis

  • 9.1. Nicotine Transdermal Patch (Nicoderm CQ)
  • 9.2. Oxybutynin Transdermal Patch (Oxytrol)

10. Global Transdermal Patch Clinical Pipeline Overview

  • 10.1. By Phase
  • 10.2. By Region/Country
  • 10.3. By Drug Class/Molecule
  • 10.4. By Company
  • 10.5. By Orphan & Fast Track Status
  • 10.6. By Mode of Action

11. Global Patch Clinical Pipeline By Company, Indication & Phase

  • 11.1. Unknown
  • 11.2. Research
  • 11.3. Preclinical
  • 11.4. Clinical
  • 11.5. Phase-I
  • 11.6. Phase-I/II
  • 11.7. Phase-II
  • 11.8. Phase-III
  • 11.9. Preregistration
  • 11.10. Registered

12. Marketed Transdermal Patch Clinical Insight

13. Global Transdermal Patch Market Dynamics

  • 13.1. Favorable Market Parameters
  • 13.2. Commercialization Challenges

14. Global Transdermal Patch Market Future Outlook 2026

15. Competitive Landscape

  • 15.1. 3M Pharmaceuticals
  • 15.2. Acrux
  • 15.3. Agile Therapeutics
  • 15.4. Allergan
  • 15.5. ANI Pharmaceuticals
  • 15.6. Antares Pharma
  • 15.7. Bayer HealthCare Pharmaceuticals
  • 15.8. Corium International
  • 15.9. Chase Pharmaceuticals
  • 15.10. DURECT Corporation
  • 15.11. Endo Pharmaceuticals
  • 15.12. Fempharm
  • 15.13. Hisamitsu Pharmaceutical
  • 15.14. Immune Pharmaceuticals
  • 15.15. Imprimis Pharmaceuticals
  • 15.16. Ipsen Bioscience
  • 15.17. Johnson & Johnson
  • 15.18. LaSalle Laboratories
  • 15.19. Lavipharm-increase
  • 15.20. MINRAD International
  • 15.21. NeurogesX
  • 15.22. Noven Pharmaceuticals
  • 15.23. NuPathe
  • 15.24. Nuvo Research
  • 15.25. Novartis
  • 15.26. Pain Therapeutics
  • 15.27. ProStrakan
  • 15.28. Purdue Pharma
  • 15.29. Sanofi
  • 15.30. Scilex Pharmaceuticals
  • 15.31. Senju Pharmaceutical
  • 15.32. Somerset Pharmaceuticals
  • 15.33. Teikoku Seiyaku
  • 15.34. Therapeutic Discovery Corporation
  • 15.35. Transdermal Delivery Solutions Corp
  • 15.36. UCB
  • 15.37. Xel Pharmaceuticals
  • 15.38. Zosano Pharma

List of Figures

  • Figure 1-1: Steps Involved in Transdermal Permeation
  • Figure 1-2: Ideal Properties of Transdermal Patch
  • Figure 2-1: Types of Commercially Available Transdermal Patch
  • Figure 3-1: Properties of Transdermal Therapeutics
  • Figure 3-2: Components of Transdermal Patch
  • Figure 3-3: Types of Permeation Enhancers
  • Figure 3-4: Schematic Representation of Iontophoresis
  • Figure 3-5: Mechanism of Scopolamine Transdermal Patch
  • Figure 3-6: Mechanism of Nicotine Transdermal Patch
  • Figure 3-7: Mechanism of Female Contraceptive Transdermal Patch
  • Figure 3-8: Issues with Traditional Drug Delivery Methods
  • Figure 3-9: Advantages of Transdermal Patch
  • Figure 3-10: Consistent Drug Supply by Transdermal Patch
  • Figure 4-1: Global - Transdermal Patch Market Opportunity (US$ Billion), 2019 - 2026
  • Figure 4-2: Global - Transdermal Patch Market Share by Product (%), 2019
  • Figure 4-3: Transdermal Patch Market Size - Global vs. US (US$ Billion), 2019
  • Figure 4-4: Transdermal Patch Market Size - US vs. Rest of World (%), 2019
  • Figure 4-5: US - Transdermal Patch Market Opportunity (US$ Billion), 2019 - 2026
  • Figure 4-6: Global Nicotine Transdermal Patch Market Share - Europe vs. Rest of World (%), 2019
  • Figure 5-1: Catapres - TTS - Price for 4 Transdermal Film Supply of 0.1mg, 0.2mg & 0.3mg Dose (US$), November'2019
  • Figure 5-2: Catapres - TTS - Price per Unit of 0.1mg, 0.2mg & 0.3mg Dose Transdermal Patch (US$), November'2019
  • Figure 5-3: Catapres - TTS - Monthly & annual Treatment cost using 0.1mg dose (US$), November'2019
  • Figure 5-4: Nitro TD Patch A - Price for 30 Patch supply & Price per Unit (US$), November'2019
  • Figure 5-5: Minitran & Nitro-Dur - Price for 30 Patch Supply of 0.1mg, 0.2mg, 0.4mg & 0.6mg Transdermal Patches (US$), November'2019
  • Figure 6-1: Duragesic - Price for 5 Patch Supply of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), November'2019
  • Figure 6-2: Duragesic - Price per Unit of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), November'2019
  • Figure 6-3: Butrans - Price for 4 Patch Supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), November'2019
  • Figure 6-4: Butrans - Price per Unit of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), November'2019
  • Figure 6-5: Generic Buprenorphine Transdermal Patch - Price for 4 Patch supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), November'2019
  • Figure 7-1: Emsam - Price for 30 Patch Supply & Price per Unit of Various Doses of Emsam Transdermal Patches (US$), November'2019
  • Figure 7-2: Emsam - Monthly & Annual Treatment Cost of Parkinson's Disease (US$), November'2019
  • Figure 7-3: Transderm-Scop - Price for a Supply of 4, 10 & 24 Patches of 1.5mg Transdermal Film (US$), November'2019
  • Figure 7-4: Generic Scopolamine Transdermal Patch - Price for a Supply of 4, 10 & 24 Patches of 1.3mg Transdermal Film (US$), November'2019
  • Figure 7-5: Generic Scopolamine Transdermal Patch - Price for a Supply of 4, 10 & 24 Patches of 1.5mg Transdermal Film (US$), November'2019
  • Figure 7-6: Exelon - Price for 30 Transdermal Patch Supply of Exelon (US$), November'2019
  • Figure 7-7: Generic Rivastigmine Transdermal Patch - Price for a Supply of 30 Patches of Dose 4.6mg, 9.5mg & 13.3 mg (US$), November'2019
  • Figure 7-8: Exelon - Initial & Maintenance Dose for the Treatment of Alzheimer & Parkinson's Disease
  • Figure 7-9: Exelon - Monthly & Annual Treatment Cost for Treatment of Alzheimer & Parkinson's Disease
  • Figure 7-10: Daytrana - Patent Issue & Expiration Year
  • Figure 7-11: Daytrana - Price for 30 Transdermal Patch Supply of All Doses (US$), November'2019
  • Figure 8-1: Alora - Price for a Supply of 8 Patches of Dose 0.025mg, 0.05mg, 0.075mg & 0.1mg (US$), November'2019
  • Figure 8-2: Alora - Price per Unit of 0.025mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch(US$), November'2019
  • Figure 8-3: Alora - Recommended Dose for Treatment of vaginal Atrophy & Postmenopausal Osteoporosis (mg/Day Twice in a Week), November'2019
  • Figure 8-4: Vivelle-Dot - Price for a Supply of 24 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg (US$), November'2019
  • Figure 8-5: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch (US$), November'2019
  • Figure 8-6: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, & Postmenopausal Osteoporosis (mg/Day), November'2019
  • Figure 8-7: Androderm - Price for 60 patch Supply & per Unit Price of 2mg Transdermal Patch (US$), November'2019
  • Figure 8-8: Androderm - Price for 30 patch Supply & per Unit Price of 4mg Transdermal Patch (US$), November'2019
  • Figure 8-9: Androderm - Recommended Initial & Maintenance Dose For Treatment of Hypogonadism (mg/day), November'2019
  • Figure 8-10: Ortho Evara - FDA approval & Withdrawal Year
  • Figure 8-11: Xulane - Price for a Supply of 3 Patches & Price per Unit of 35mcg-150mcg Transdermal Patch (US$), November 2019
  • Figure 8-12: Xulane - Recommended Schedule for Achieving Birth Control Effect (Days)
  • Figure 9-1: Nicoderm CQ - Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), November'2019
  • Figure 9-2: Nicoderm CQ - Price per Unit of 7mg, 14mg & 21mg Transdermal Patch (US$), November'2019
  • Figure 9-3: Nicoderm CQ - Recommended Dose & Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)
  • Figure 9-4: Nicoderm CQ - Recommended Dose & Treatment Schedule for Patients with Consumption of Less Than 10 Cigarette/Days (mg/day)
  • Figure 9-5: Nicoderm CQ - Full Treatment Cost for Patient with Daily Consumption of Less than 10 Cigarettes & More than 10 Cigarettes (US$), November'2019
  • Figure 9-6: Oxytrol - Patent Issue & Expiration Year
  • Figure 9-7: Oxytrol - Price of 4 Patch Supply & Price per Unit of 3.9mg Transdermal Patch (US$), November'2019
  • Figure 9-8: Oxytrol - Price of 8 Patch Supply & Price per Unit of 3.9mg Transdermal Patch (US$), November'2019
  • Figure 10-1: Global - Transdermal Patch Pipeline by Phase (%), 2019 till 2026
  • Figure 10-2: Global - Transdermal Patch Pipeline by Phase (Number), 2019 till 2026
  • Figure 10-3: Global - Transdermal Patch Pipeline by Region (%), 2019 till 2026
  • Figure 10-4: Global - Transdermal Patch Pipeline by Country (Number), 2019 till 2026
  • Figure 10-5: Global - Transdermal Patch Pipeline by Drug Class/Molecule (%), 2019 till 2026
  • Figure 10-6: Global - Transdermal Patch Pipeline by Company (%), 2019 till 2026
  • Figure 10-7: Global - Transdermal Patch Pipeline by Orphan & Fast Track Status (%), 2019 till 2026
  • Figure 10-8: Global - Transdermal Patch Pipeline by Mode of Action (%), 2019 till 2026
  • Figure 13-1: Drivers for Transdermal Patch
  • Figure 13-2: Transdermal Patch Market Commercialization Challenges
  • Figure 15-1: Acrux Clinical Pipeline
  • Figure 15-2: Agile Therapeutics Clinical Pipeline
  • Figure 15-3: Antares Pharma Clinical Pipeline
  • Figure 15-4: Corium International Clinical Pipeline
  • Figure 15-5: Durect Corporation Clinical Pipeline
  • Figure 15-6: Endo Pharmaceuticals Clinical Pipeline
  • Figure 15-7: Immune Pharmaceuticals Clinical Pipeline
  • Figure 15-8: Novartis Clinical Pipeline
  • Figure 15-9: Senju Pharmaceuticals Clinical Pipeline
  • Figure 15-10: Xel Pharmaceuticals Clinical Pipeline
  • Figure 15-11: Zosano Pharma Clinical Pipeline
  • List of Tables
  • Table 2-1: Differences between Active & Passive Transdermal Patches
  • Table 4-1: Transdermal Patches for Various Disease Indications
  • Table 8-1: Duragesic - Initial Dose Conversion from Other Opioids
  • Table 8-2: Butrans - Initial Dose Calculation using Previous Opioid (Morphine) Dosage
  • Table 9-1: Daytrana - Dose Increment Pattern for Treatment of ADHD
  • Table 15-1: Pain Therapeutics Clinical Pipeline
Back to Top